A CYP450 enzyme is part of a liver and gut enzyme family that helps metabolize many medications, hormones, and other compounds.
Why the family matters
CYP450 enzymes are central to first-pass and systemic metabolism. Variation in these enzymes, enzyme inhibition, enzyme induction, and medication overlap can all change exposure. That makes CYP context relevant to first-pass metabolism and safety review.
Common examples
CYP3A4, CYP2D6, CYP2C9, CYP2C19, and CYP1A2 are among the enzymes that appear often in medication references. Some are affected mostly by co-administered compounds, and some also have clinically used genetic categories. The exact meaning depends on the medication and evidence source.
Why supplement users should be cautious
A supplement or food component can sometimes inhibit or induce an enzyme that a medication also uses. That does not mean every overlap is dangerous, but it does mean the overlap belongs in interaction checks, especially for medications with narrow safety margins.
Relation to pharmacogenomics
Pharmacogenomics may report a user as a poor, intermediate, normal, rapid, or ultrarapid metabolizer for some enzyme-drug pairs. Those categories are medication-specific context, not broad rules for all supplements or all stacks.
How this appears in Unfair
Unfair can use CYP450 context to flag uncertainty, route users toward medication review, or lower recommendation confidence when an overlap is unresolved. It should not suggest medication dose changes or treat enzyme status as a stand-alone ranking rule.
Safety note
Users taking prescription medications should review CYP-related supplement questions with a clinician or pharmacist before changing either side of the routine.